A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas

NCT00001564 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

NIH

Sponsor class

Conditions

Ewing's Sarcoma
Rhabdomyosarcoma

Interventions

DRUG: EF-1 Peptide
DRUG: EF-2 Peptide
DRUG: PXFK Peptide
DRUG: E7 Peptide
DRUG: IL-2
DRUG: IL-4
DRUG: GM-CSF
DRUG: CD40 Ligand

Sponsor

National Cancer Institute (NCI)